Acelyrin (NASDAQ: SLRN) is a late-stage clinical biopharma company that cratered in pre-market trading after announcing disappointing topline results from Part B of a Phase 2b trial evaluating izokibep. Izokibep is used in the treatment of moderate-to-severe Hidradenitis Suppurativa (HS). Hidradenitis Suppurativa (HS) is a chronic skin condition resulting in skin lesions in places such as the armpit or groin.
The trial did not meet the primary endpoint of HiSCR75 at week 16. However, the company stated in its press release that, “response rates for izokibep showed early HiSCR100 responses, a clear dose-effect supported by both pharmacokinetic exposures and HiSCR responses favoring 160mg weekly dosing, and no evidence of safety or tolerability limitation.”
Shao-Lee Lin, MD, PhD, founder and CEO of ACELYRIN commented, “The consistent and early achievement of HiSCR100, along with our prior izokibep experience in Psoriatic Arthritis, continues to demonstrate the potential of izokibep for resolution of disease, especially in difficult to treat tissues. These results further support our ongoing evaluations of 160 mg QW dosing in HS, as well as for additional indications, including uveitis and PsA, the largest potential indication for izokibep.”
However, analysts remain bullish about the SLRN stock even with this setback and have a consensus rating of Strong Buy with four unanimous Buys.
